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Studies on Pf332, a major Plasmodium falciparum blood-stage antigen, have largely been hampered by the cross-reactive nature
of antibodies generated against the molecule due to its high content of repeats, which are present in other malaria antigens. We
previously reported the identiﬁcation of a conserved domain in Pf332 with a high degree of similarity to the Duﬀy-binding-
like (DBL) domains of the erythrocyte-binding-like (EBL) family. We here describe that antibodies towards Pf332-DBL are
induced after repeated exposure to P. falciparum and that they are acquired early in life in areas of intense malaria transmission.
Furthermore,ahomologymodelofPf332-DBLwasfoundtobesimilartothestructureoftheEBL-DBLs.Despitetheirsimilarities,
antibodies towards Pf332-DBL did not display any cross-reactivity with EBL-proteins as demonstrated by immunoﬂuorescence
microscopy, Western blotting, and peptide microarray. Thus the DBL domain is an attractive region to use in further studies on
the giant Pf332 molecule.
1.Introduction
Plasmodium falciparum malaria is a major human disease
thataccountsfor1–2milliondeathsannually[1].Thedisease
aﬀects predominantly children under the age of ﬁve, as
older children and adults living in malaria endemic areas
become immune against severe forms of the disease after
being repeatedly exposed to the parasite.
During blood-stage development, P. falciparum parasites
invade red blood cells (RBC) and cause them to sequester
from the blood circulation by adhering to host endothelial
cells. Both invasion and sequestration are central to the
pathogenesis of malaria, and they require an adhesive
cysteine-rich domain referred to as the Duﬀy-binding-like
(DBL) domain. The DBL domains are present in two
diﬀerentproteinfamilies;theerythrocyte-binding-like(EBL)
family of invasion proteins and the large and diverse
P. falciparum erythrocyte membrane protein 1 (PfEMP1)
family of cytoadherence proteins [2, 3]. We recently reported
the identiﬁcation of a previously unknown domain in the
P. falciparum antigen 332 with a high degree of similarity
to the DBL domains of the EBL family [4]. Most EBL
members are transmembrane proteins, which are expressed
in schizonts and localize to merozoite micronemes from
where they are released prior to or during host cell invasion
[5]. In contrast, Pf332 is expressed in trophozoites and is
later on cotransported together with the surface-destined
PfEMP1 in parasite-induced membrane structures, referred
to as Maurer’s clefts [6, 7]. In schizonts, Pf332 can be found
in association with the RBC plasma membrane, although it2 Malaria Research and Treatment
is not clear whether the antigen becomes surface exposed
or not [4, 7]. Pf332 is a large protein of approximately
700kDa consisting predominantly of degenerate repeats rich
in glutamic acid (Glu) [8–10]. Pf332 further lacks the typical
EBL gene structure with the tandem DBL domains and the
cysteine-rich region adjacent to the transmembrane domain
[3]. In Pf332, the single DBL domain is located in the
N-terminus of the protein and is followed by a putative
transmembrane region and a large number of negatively
charged Glu-repeats, which make up a major part of the
molecule (Figure 1(a))[ 4]. In addition, Pf332 has a C-
terminal tryptophan-rich region (WRD) with similarities to
WRDs found in SURFINS, PkSICAvar, and PfEMP1 [11].
Although the function of Pf332 is not clear, the antigen is
present in all isolates investigated [4, 10], indicating that it is
of importance for the parasite.
Previous studies on Pf332 have primarily focused on
EB200, a 157 amino-acid-long Glu-rich fragment, located
in the central repeat region of the protein (Figure 1(a))[ 9].
Individuals living in malaria endemic areas have been shown
to have antibodies recognizing this region [12, 13] and these
antibodies were associated with fewer clinical malaria attacks
[14]. However, antibodies recognizing the repeat regions in
Pf332arepossiblycross-reactivewithotherGlu-richantigens
in P. falciparum such as Pf155/RESA, making it diﬃcult to
ascertain the antibody speciﬁcity. Therefore, there is a need
for a more speciﬁc Pf332 marker. The DBL domain of Pf332
is conserved between diﬀerent parasite strains but with a
distinct sequence, as compared to the DBL domains of the
EBL family [4]. The conservation and distinct sequence of
theDBLregionmakesitanattractivetargetformoredetailed
and speciﬁc studies on the molecule Pf332.
In the present study, we have expressed soluble Pf332-
DBL recombinant protein in Escherichia coli and analyzed
its folding and secondary structure content by circular
dichroism (CD) spectroscopy. We have further created a
homology model of Pf332-DBL in order to assess structural
similarities to the DBL domains of the EBL family. The
predicted three-dimensional structure was found to have a
fold similar to the DBL domains of P. falciparum EBA-175
and P. knowlesi Duﬀy-binding protein, which was in good
agreement with the measured CD data. We have further
examined naturally acquired antibodies towards the DBL
domain of Pf332 and a DBL1α-domain from the variant
surface antigen PfEMP1 [15], in order to get a better insight
into the immunogenicity of the DBL domain of Pf332. We
here show that Pf332 is widely recognized in distinct malaria
endemic regions and that antibodies towards Pf332-DBL do
not display any cross-reactivity with DBL-containing EBL
proteins. This makes the DBL domain an attractive region
to use in further studies on the Pf332 molecule.
2. Methods
2.1. Cloning, Expression, and Puriﬁcation of Pf332-DBL and
PfEMP1-DBL1α. The DBL1α-domain of var1FCR3S1.2 and
the DBL domain of Pf332 were ampliﬁed with oligo-
nucleotide primers (F-DBLFCR3S1.2 CCATGG CTA CTT CCG
GAG GA, R-DBLFCR3S1.2 AGATCT GAGACG GTA CTT CTT
CTG CTT ATC; F-DBL3D7PF332 GCATGC GAA GCA ACA
TCA ACA ACA AGG, R-DBL3D7PF332 GGATCC GTA CTT
CTT CTC GAA CAC C) from genomic DNA and cloned
into the NcoI and BglII or SphI and BamHI restriction site
of the pQE60 or pQE70 vector (Qiagen, D¨ usseldorf, Ger-
many),respectively.His-taggedrecombinantPf332-DBLand
var1FCR3S1.2-DBL1α proteins were expressed according to
standard procedures with modiﬁcations. Brieﬂy, SG13009
E. coli (Qiagen) were grown in LB medium until OD600
reached 0.8–1.0, and the culture was subsequently induced
with 100μM IPTG and grown for an additional 3h at room
temperature. The bacteria were harvested by centrifugation
at 990g for 20min, after which the pellet was resuspended in
washing buﬀer (20mM HEPES (pH 7.4), 30mM imidazole,
and 500mM NaCl). 1mg/mL lysozyme (BioSite, San Diego,
CA, USA) was added, to the lysate, which was incubated for
30minonice.CompleteCocktailproteaseinhibitors(Roche,
Basel, Switzerland) were added and the cells were broken by
sonicationonice.Thelysatewasclariﬁedbycentrifugationat
13250g for 20min, after which the supernatant was collected
and ﬁltered through a 0.45μm ﬁlter.
For protein puriﬁcation, a His GraviTrap column (GE
Healthcare, Uppsala, Sweden) was used, according to the
manufacturer’s instructions. The cleared lysate was loaded
onto the column and allowed to pass through twice. The
column was washed extensively with washing buﬀer and the
bound protein eluted with elution buﬀer containing 20mM
HEPES (pH 7.4), 500mM imidazole, and 500mM NaCl.
All eluted fractions of Pf332-DBL were analyzed by SDS-
PAGE using a 12% separation gel, and fractions containing
the highest concentration of pure protein were pooled,
dialyzed overnight against phosphate buﬀered saline (PBS),
and ﬁnally concentrated using Centriprep centrifugal ﬁlter
units (Millipore, Billerica, MA, USA). Possible aggregates of
Pf332-DBL were thereafter spun down (5min at 16060g)
and the supernatant was applied to a 16/60 Superdex 200
size exclusion chromatography column (GE Healthcare),
equilibrated with 20mM HEPES (pH 7.5), 300mM NaCl,
and 10% glycerol at a ﬂow rate of 0.5mL/min. The elution
was followed by UV absorbance at 280nm, and the peak
fractions were collected and analyzed by SDS-PAGE, as
above. Fractions containing the highest concentration of
pure protein were pooled and concentrated. The identity of
the puriﬁed protein was conﬁrmed by mass spectrometry
using the Royal Institute of Technology (KTH, Stockholm,
Sweden) mass spectrometry core facility.
2.2. Circular Dichroism Spectroscopy. Circular dichroism
(CD) spectroscopy measurements of Pf332-DBL in PBS (pH
7.4) were conducted on a JASCO J-810 spectropolarimeter,
using a cuvette with a 0.1cm path length. The spectra
were accumulated from eight scans at 20◦C, using a 0.1nm
data pitch, 1s signal response time, and a 1nm bandwidth.
Data were recorded in the far UV region from 195 to
260nm. The scanning speed was 20nm/min and sensitivity
100mdeg. The average spectra were corrected by subtracting
the background spectrum measured for the buﬀer.Malaria Research and Treatment 3
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Figure 1: Puriﬁcation and characterization of recombinant Pf332-DBL. (a) Schematic representation of the full-length Pf332 protein.
Residues 1–570 are encoded by the ﬁrst exon, which contains the Duﬀy-binding-like (DBL) domain (white) and the predicted
transmembrane domain (black). Exon 2 encodes the extensive glutamic acid-rich repeat region (grey), which contains the repetitive EB200
region(lightgray)andthetryptophan-richWRDregion(striped).(b)Coomassie-stainedSDSpolyacrylamidegelaftereachpuriﬁcationstep
ofPf332-DBL.Lane1:E.colisolublelysate,lane2:afteraﬃnitypuriﬁcationonaNi-column,andlane3:aftersizeexclusionchromatography.
Bands corresponding to recombinant Pf332-DBL protein are indicated. (c) Mass spectrum proﬁle of Pf332-DBL after size exclusion
chromatography to verify purity. One major ion peak at m/z 26935 can be visualized. (d) Circular dichroism spectrum of Pf332-DBL in
the far UV region, demonstrating that the protein is folded and consisting predominantly of α-helices, as indicated by a positive band at
195nm and two negative bands at 208 and 220nm.
2.3. Tertiary Structure Modeling of Pf332-DBL. Ah o m o l o g y
model of 3D7 Pf332-DBL (PF11 0506 amino acids 1–255)
was constructed using the HHpred server [16]w i t hd e f a u l t
settings. Brieﬂy, the HHpred method is specialized in detect-
ing homology using Hidden Markow Models built from
PSI-BLAST proﬁles and secondary structure. The crystal
structure of the EBA-175 F2-domain was used as a template
(Protein Data Bank code 1ZRO [17]c h a i nA[ 18]. The
alignment was manually adjusted at positions 180 and 254 to
align two cysteines, which are in close proximity, to allow for
the modeling of two disulphide bridges conserved in PfEBA-
175 and Pkα-DBP. MODELLER 9v3 [19] and the MPI-
toolkit were used to create the model. Structure visualization
was made in PyMol [21]. The model was validated by using
the PROCHECK program [22], available in the SWISS-
MODEL Workspace [23] and Verify3D, available in the
HHpred server toolkit [16].
2.4. Plasma Samples
Plasma Samples from Adult Donors. In Uganda, plasma sam-
ples were collected from women over 18 years, taking part of
a cross-sectional investigation in 2006 on malaria infection
in pregnancy at Mulago Hospital, Uganda’s national referral
hospital in Kampala [24]. Ethical permissions have been
obtained both in Sweden and Uganda (permit number 04-
533/2 and MV922). In Mali, plasma samples were collected
at the end of the malaria transmission season in November
2001 in the malaria mesoendemic Mopti area [25]. Adult
donorsbelongedtodiﬀerentsympatricethnicgroups(Fulani
and Dogon) living 300–1000m apart. In Burkina Faso,
plasma samples were collected during the peak of malaria
transmission season in September and October 1999 in
a malaria holoendemic area outside Ouagadougou, the
capital of Burkina Faso [25]. Adult donors belonged to
either the Fulani group or the Mossi group. Studies in
both Mali and Burkina Faso have shown that the Fulani
tribe is less parasitized, has higher levels of antimalaria
antibodies, and suﬀers from fewer malaria attacks compared
to the Mossi and Dogon tribes despite the same level of
malaria transmission [26–28]. Ethical permissions have been
obtained both in Sweden and Mali (permit number 03-536
and 1866/FMPOS) and Burkina Faso (permit number 98-
086 and 9800839/MS/SG/DEP).
Plasma Samples from Children. Plasma samples were col-
lected in 2002 from children under the age of ﬁve with
an ongoing P. falciparum infection in Apac, a malaria4 Malaria Research and Treatment
holoendemic area [29] 250km north of Kampala, Uganda
[30]. Children were identiﬁed with mild or severe malaria
according to WHO guidelines [31] and the modiﬁed Blan-
tyre scale [32]. Ethical permissions for the study have been
obtained both in Sweden and Uganda (permit number
03/095 and MV717).
2.5. Enzyme Linked-Immunosorbent Assay (ELISA). Anti-
body responses were measured by enzyme linked-immun-
osorbent assay (ELISA). Maxisorp plates (Nunc, Roskilde,
Denmark) were coated overnight at 4◦C with antigens
dissolved in 15mM Na2CO3 a n d3 5m MN a H C O 3 (pH 9.6)
at a concentration of 10μg/mL. The plates were blocked
with 1% bovine serum albumin (BSA) in PBS containing
0.1% Tween 20 (PBS-T) for 1h at room temperature and
subsequently washed three times with PBS-T. All plasma
samples were titrated six-fold by serial dilutions in PBS-T
to determine concentration dependency, added in duplicates
and allowed to bind for 1h at 37◦C .T h ep l a t e sw e r e
washed and bound immunoglobulin G (IgG) was detected
by incubation for 1h at 37◦C with alkaline phosphatase-
conjugated goat anti-human IgG (Sigma, St. Louis, MO,
USA) diluted 1:1000 in PBS-T. The plates were washed
and the assay developed by adding p-nitrophenyl phosphate
(Sigma) as a substrate for 15min. The optical density (OD)
was read at 405nm in an ELISA plate reader (Multiskan
EX Version 1.0, Labsystems, Stockholm, Sweden). On each
plate, a pool of plasma from 11 nonmalaria exposed Swedish
d o n o r sw a sa s s a y e da sw e l la sc o n t r o lw e l l sw i t h o u tp l a s m a
(background level). Cutoﬀ threshold for seropositivity was
determined as the mean OD405 value plus three standard
deviations from the 11 Swedish donors. Amount of IgG
was expressed as OD ratio and calculated as follows: (OD
sample − OD background)/(OD Swedish nonimmune pool
− OD background). The presented results and data used
for statistical analyses were obtained with plasma samples
diluted 1:500.
2.6. Aﬃnity-Puriﬁcation of Pf332-DBL Antibodies from
Patient Plasma. The DBL domain of Pf332 was coupled
to CNBr-activated sepharose (GE Healthcare) according
to manufacturer’s instructions and the coupled medium
slurry was thereafter degassed and packed into an empty
polystyrene column (Thermo Fisher Scientiﬁc Inc., Rock-
ford, IL, USA). For puriﬁcation, 20mL of plasma from
a pool of adult donors (reactive to Pf332-DBL in ELISA-
assays) were diluted 1:4 in degassed PBS, sterile ﬁltered, and
loaded onto the column and allowed to pass three times.
The column was washed extensively with PBS and antibodies
were eluted with 150mM glycine (pH 2.5) in 10 × 1m L
fractions and immediately neutralized with 100μL1MT r i s
buﬀer (pH 8.6). Antibody concentration was determined
spectrometrically, using the molar extinction coeﬃcient of
ε280 = 210 000M−1 cm−1 for immunoglobulins. Fractions
containingantibodieswerepooled,dialyzedagainstPBS,and
ﬁnally concentrated using Centriprep centrifugal ﬁlter units
(Millipore, Billerica, MA, USA).
2.7. Peptide Array. Slides with P. falciparum peptide epitopes
were manufactured by JPT (Berlin Germany) and consisted
of three identical subarrays. Each subarray had a set of
52 overlapping peptides of 15 amino acids shifted by four
residues covering 3D7 Pf332-DBL (PF11 0506, spanning
amino acids 1–219) and 148 overlapping peptides covering
3D7 PfEBA-175 (MAL7P1.176, spanning amino acids 145–
747). The peptides were bound chemoselectively to the
microarray surface by coupling of an active amine (from the
peptide) to an epoxy-group (from the slide surface). The
slides were hybridized with 5μg/mL human IgG or human
aﬃnity-puriﬁed Pf332 antibodies diluted in PBS containing
3% fetal calf serum and 0.5% Tween 20 (PBS-T) in a humid
chamber for 16h at 4◦C. Next, the microarray slides were
washedﬁvetimes:twotimeswithPBS-Tandthreetimeswith
distilled water. The slides were subsequently incubated with
a secondary Cy5-coupled goat anti-human antibody (1:500;
Jackson ImmunoResearch, Suﬀolk, United Kingdom) for
2h at room temperature in a humid chamber, followed by
washing steps. The slides were scanned in a GenePix 4000B
microarray scanner (Axon Instruments Inc., Foster City, CA,
USA) at a wavelength of 635nm and images were saved
in TIFF and JPG formats. Image analysis was performed
utilizingthecircularfeaturealignmentoftheGenePixPro6.0
software(AxonInstrumentsInc.)andtheGenePixArrayList
(GAL) ﬁles supplied by JPT. To measure antibody response,
the mean ﬂuorescence intensity given by the diﬀerence
between the foreground and the local background of the
circular features were used. Data presented represent the
average of the three subarrays.
2.8. Parasite Cultures and Kinetic Studies on Synchronous Par-
asite Populations. P. falciparum clone FCR3S1.2 was main-
tained in continuous culture according to standard proce-
dures [33]. Brieﬂy, parasites were cultivated at a 5% hema-
tocrit in malaria culture medium supplemented with 10%
Swedish nonimmune A+ serum. Parasites were synchronized
with sorbitol treatment and synchronous parasites were
harvested at diﬀerent time-points for indirect immunoﬂu-
orescence assays and Western blot.
2.9. Indirect Immunoﬂuorescence Assay for Detection of Pf332.
For immunoﬂuorescence assays, monolayers of synchronous
FCR3S1.2 infected RBC (iRBC) were prepared as previously
described. Monolayers were blocked for 1h with 3% BSA
in PBS and subsequently incubated for 1h with aﬃnity-
puriﬁed human anti-Pf332-DBL (1:2000), polyclonal rabbit
anti-Pf332-EB200 (1:500), polyclonal rabbit anti-MAHRP1
(1:10, kind gift from Hans-Peter Beck), monoclonal mouse
anti-Pf332-DBL (1:800), or polyclonal rabbit anti-EBA
175 RVI (1:1600, kind gift from John H. Adams), all
diluted in blocking buﬀer. Slides were thereafter washed
three times with PBS and primary antibodies were detected
by incubation for 1h with secondary ALEXA-Fluor 594-
conjugated anti-human IgG, ALEXA-Fluor 488-conjugated
anti-rabbit IgG or ALEXA-Fluor 594-conjugated anti-mouse
IgG (dilution 1: 1000; Invitrogen, Carlsbad, CA, USA). ToMalaria Research and Treatment 5
avoid photobleaching, cells were mounted with Vectashield
(Vector Laboratories, Burlingame, CA, USA) containing
1.5μg/mL 4 ,6-diamidino-2-phenylindole (DAPI) to stain
for parasite DNA. All incubations were performed at room
temperature in a humid chamber. Cells were viewed with
a 100 × oil immersion objective in a UV equipped Nikon
Eclipse 90i/80i microscope (Nikon Corporation, Japan) and
images were captured by a Hamamatsu Orca-ER CCD
Digital camera (Hamamatsu Photonics System, Japan) and
MicroManager software version 1.3 (developed by Arthur
Edelstein, Nico Stuurman and Nenad Amodaj, University
of California, San Francisco, USA). All images were ﬁnally
processed using ImageJ software version 1.43 (National
Institutes of Health, Bethesda, USA).
2.10. Immunodetection of Pf332 in Western Blot. FCR3S1.2
trophozoites 24h after invasion (p.i.) were enriched by mag-
netic cell sorting (Miltenyi Biotec, Bergisch Gladbach, Ger-
many) and returned into culture to reach approximately 36–
40h p.i. Samples were lysed in SDS-loading buﬀer, separated
on a 6% SDS-PAGE (2.5 × 105 iRBC/lane) and transferred
onto nitrocellulose membranes (Bio-Rad, Hercules, CA,
USA).Membraneswereprobedwithaﬃnity-puriﬁedhuman
anti-Pf332-DBL (1:3000), anti-EB200 (1:1000), and mon-
oclonal anti-Pf332-DBL (1:100). Detection by enhanced
chemiluminescence (ECL plus Western blotting detection
reagents, GE Healthcare) was performed after a secondary
probe of HRP-coupled anti-human IgG, antirabbit IgG, or
anti-mouse IgG (1:5000, GE Healthcare) were added.
2.11. Statistical Analyses. Statistical analyses were performed
with Prism version 5.0 (Graphpad Software, San Diego,
USA). Chi-square test was used when comparing the sero-
prevalence.Student’spairedt-testorWilcoxonsignedranked
test (when samples were not normally distributed) was used
when comparing antibody levels within the same group.
Student’s unpaired t-test or Mann-Whitney test (when
samples were not normally distributed) was used when
comparing antibody levels between diﬀerent groups.
3. Results
3.1. Puriﬁcation and Characterization of Pf332-DBL Recom-
binant Protein. The DBL domain of Pf332 was expressed
in E. coli as a His-tagged recombinant protein and puriﬁed
by Ni-aﬃnity chromatography, followed by size exclu-
sion chromatography. A band migrating at approximately
27kDa could be visualized on the Coomassie-stained SDS-
polyacrylamide gel from the soluble E. coli lysate, as well as
from the eluted fractions after aﬃnity puriﬁcation and size
exclusion chromatography (Figure 1(b)). The protein eluted
from the size exclusion column at an elution volume of
90mL,whichcorrespondstothesizeofamonomer.Toverify
the molecular mass of the puriﬁed protein, analysis by mass
spectrometry was conducted. The mass spectra showed one
major ion at m/z 26935, which corresponds to the theoretical
weight of Pf332-DBL (Figure 1(c)).
To evaluate the folding state and secondary structure
content of the recombinant protein, CD spectra were
measured in the far UV region. The spectra indicate that
the protein is folded, and the shape of the spectra, with a
positive band at 195nm and two negative bands at 208 and
220nm, respectively, is typical for proteins with a high α-
helical content (Figure 1(d))[ 34].
3.2. Homology Modeling of the Structure of the Pf332
DBL-Domain. Crystal structures of two diﬀerent EBL-DBL
domains have been determined, namely, the tandem DBL
domains of P. falciparum EBA-175 (F1 and F2) [18]a n d
the single DBL domain of P. knowlesi Duﬀy-binding protein
(Pkα-DBL)[35].UsingthecrystalstructureofEBA-175F2as
a template (PDB code 1ZRO [18]), a three-dimensional (3D)
model of Pf332-DBL was constructed by comparative mod-
eling on the basis of the 3D7 sequence (PF11 0506, amino
acids 1–255) in Modeller 9v3 [19]. The HHpred probability
score for EBA-175 F2 to be used as a template for Pf332-DBL
modeling was 100%, although the sequence identity between
the two domains was only 29% (Figure 2(a)). The model
was validated by using the PROCHECK program [22]a n d
Verify3D [16].ThePROCHECKRamachandranplotshowed
that 90.1% of the residues in the model were in the core
region, 9.1% in the allowed region, 0.4% in the generously
allowed region, and 0.4% in the disallowed region, proving
that the 3D model was of good quality. Analysis using
Verify3D resulted in a similar conclusion (score > 0.1).
The homology model of Pf332-DBL consists predomi-
nantly of α-helices, which is in accordance with our CD-
spectrum (Figure 2(b)). The model further adopts a basic
fold similar to both the DBL domains of EBA-175 [18]a n d
Pkα-DBL [35]. Of the twelve cysteine residues present in
Pf332-DBL, ten correspond in location to cysteines in EBA-
175 F2 and eight to cysteines shared between EBA-175 F1,
F2, and Pkα-DBL (Figure 2(a)). Five disulphide bridges were
further identiﬁed in the model and four of them were found
to be conserved in EBA-175 F1, F2, and Pkα-DBP whilst the
ﬁfth was only found in EBA-175 F2. Since our homology
model of Pf332-DBL is structurally similar to EBL-DBLs,
we used the Singh et al. nomenclature [35] and divided
the Pf332-DBL domain into three subdomains (Figure 2(c)).
In the model, a random-coil stretch of residues constitutes
subdomain 1. All DBL domains crystallized to date have four
invariantcysteineresiduesformingtwoconserveddisulphide
bridges in this subdomain. Pf332-DBL, however, lacking
two of these cysteines (Cys 1 and 4; Figure 2(a)), only has
one disulphide bridge in this region (Cys 2–3; Figure 2(c)).
Subdomain 2 of the Pf332 model contains four α-helices
connected by loops. One conserved disulphide bridge could
be identiﬁed in the subdomain (Cys 5–6; Figure 2(c))a s
well as two unpaired cysteines (Cys 5∗ and 6∗), which were
foundtobeuniqueforPf332-DBL(Figure 2(a)).Subdomain
3 has one short stretch of α-helices but the subdomain is
dominated by its two long antiparallel α-helices that are
connected by a loop. The third subdomain is predicted to
be held together by three disulphide bridges, two of which
are conserved among all DBL domains studied here (Cys 8–6 Malaria Research and Treatment
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Figure 2: Homology model of Pf332-DBL created using EBA-175 as a template. (a) Sequence alignment of PfEBA-175 F1 and F2 (amino
acids 152–426 and 460–743, resp.), Pkα-DBL (amino acids 15–317) and Pf332-DBL (amino acids 1–255). The sequence identity between
Pf332 and EBA-175 F1, F2, and Pkα-DBL is 26%, 29%, and 24%, respectively. Cysteines are numbered according to the occurrence in the
EBA-175 F2 template. Of the twelve cysteines encoded by Pf332-DBL, eight are conserved between all DBL domains investigated here (Cys
numbering displayed in red), two are conserved with only EBA-175 F2 (marked with white arrowheads) whilst the remaining two are unique
for Pf332-DBL (numbering marked with an asterisk). Cysteines that are missing in the Pf332-DBL domain but that are present in EBA-175
F1, F2, and Pkα-DBL are marked with black arrowheads. (b) Homology model of Pf332-DBL (PF11 0506 amino acids 1–255) created using
EBA-175 F2 (PDB code 1ZRO) as a template. Cysteines are shown in yellow, and residues predicted to be involved in disulphide bridges are
shown as spheres. (c) The predicted Pf332-DBL model can be subdivided into three subdomains; subdomain 1 (yellow), subdomain 2 (red),
and subdomain 3 (green). Subdomains 1 and 2 have one disulphide bridge each (Cys 2-3 and Cys 5-6, resp.) whilst subdomain 3 has three
(Cys 7–12, Cys 8–10, and Cys 11–13). For Pf332-DBL, Cys 2 = Cys residue 15, Cys 3 = residue 21, Cys 5∗ = residue 69, Cys 5 = residue 73,
Cys 6∗ = residue 140, Cys 6 = residue 144, Cys 7 = residue 168, Cys 8 = residue 181, Cys 10 = residue 187, Cys 11 = residue 191, Cys 12 =
residue 235, and Cys 13 = residue 254.Malaria Research and Treatment 7
10 and Cys 11–13) and one that is shared with only EBA-
175 F2 (Cys 7–12; Figure 2(c)). The third subdomain further
lacks two cysteines that are present in all other DBL domains
studied here (Cys 9 and 14; Figure 2(a)).
3.3. Seroprevalence and Magnitude of Naturally Acquired
Antibodies to Pf332-DBL and PfEMP1-DBL1α. In order to
examine whether antibodies towards the DBL domain of
Pf332 were elicited during natural infection with P. falci-
parum, the recombinant Pf332-DBL protein was examined
together with a DBL1α-domain from the variant surface
antigen PfEMP1 in ELISA assays. Seroprevalence and anti-
body levels were analyzed in plasma samples collected from
semi-immune adults in Kampala (Uganda) and children
with either mild or severe malaria in Apac (Uganda).
We further analyzed plasma samples from asymptomatic
individualswithdiﬀerentsusceptibilitytomalaria,belonging
to sympatric ethnic groups in Burkina Faso (the Fulani
and the Mossi tribe) and Mali (the Fulani and the Dogon
tribe). As summarized in Table 1, the seroprevalence of
antibodies directed against Pf332-DBL and PfEMP1-DBL1α
was consistently high in the distinct malaria endemic regions
studied here (60–98% and 50–87%, resp.), demonstrating
the immunogenicity of the two antigens.
In Kampala, over 60% of the individuals were seropos-
itive for Pf332-DBL and PfEMP1-DBL1α (Table 1)a n d
they had acquired comparable levels of antigen-speciﬁc
antibodies (median OD ratio of immune plasma/Swedish
nonimmune plasma were 2.7 and 3.7, resp.; Figure 3(a)). In
the highly endemic area of Apac, over 71% of the children
with mild malaria and 84% of the children with severe
malaria were seropositive for the two antigens already at a
very young age (7 months to 4 years; Table 1). Moreover,
all children had acquired comparable levels of antigen-
speciﬁc antibodies, regardless of whether they had mild or
severe malaria (median OD ratio ranging from 4.0 to 4.8;
Figure 3(b)).
Adults living in Burkina Faso had the highest Pf332-DBL
seroprevalencewithover95%positiveindividualsinboththe
Fulani and the Mossi tribe (Table 1). Furthermore, individu-
als in both tribes had acquired similarly high levels of Pf332-
DBL speciﬁc antibodies (median OD ratio 7.4 in the Fulani
and 8.1 in the Mossi; Figure 3(c)) .T h es e r o p r e v a l e n c eo f
antibodiesdirectedagainstPfEMP1-DBL1αdiﬀeredbetween
the two ethnic groups and a signiﬁcantly higher proportion
ofindividualsoftheMossitribewerefoundtobeseropositive
(73% of the Mossi compared to 52% of the Fulani, P < 0.05).
The amount of antibodies speciﬁc for PfEMP1-DBL1α was,
however, similar in both tribes (median OD ratio 2.6 in the
Fulani and 3.4 in the Mossi; Figure 3(c)). When comparing
antibody levels within each ethnic group, levels of antibodies
directed against Pf332-DBL were found to be signiﬁcantly
higher than levels of PfEMP1-DBL1α antibodies in both the
Fulani and the Mossi tribe (P < 0.001).
In Mali, the seroprevalence of Pf332-DBL antibodies was
over 93% in both the Fulani and the Dogon group (Table 1)
and IgG levels were similar and very high (median OD
ratio 7.6 in the Fulani and 7.2 in the Dogon; Figure 3(d)).
Opposite to what was observed in Burkina Faso, more Fulani
than Dogon were seropositive for antibodies directed against
PfEMP1-DBL1α (71% of the Fulani compared to 50% of
the Dogon), although this diﬀerence was not signiﬁcant
(Table 1). The Fulani tribe, which is less susceptible to
malaria, had acquired signiﬁcantly higher (P < 0.01) levels
of antibodies towards PfEMP1-DBL1α than their sympatric
tribe Dogon (median OD ratio 3.2 in the Fulani and 2.7 in
the Dogon, Figure 3(d)). Similar to what was observed in
Burkina Faso, levels of Pf332-DBL antibodies were found
to be signiﬁcantly higher than levels of PfEMP1-DBL1α
antibodies in both the Fulani and the Dogon tribe (P <
0.001).
3.4.PeptideArraytoDetermineEpitopeSpeciﬁcityofNaturally
Acquired Human Pf332-DBL Antibodies. Previous studies on
Pf332 have been hampered by the potential cross-reactivity
of anti-Pf332 antibodies with other repetitive antigens [36].
In an eﬀort to evaluate the ﬁne speciﬁcity of naturally
acquired human antibodies to Pf332-DBL, we aﬃnity-
puriﬁed human antibodies speciﬁc for the Pf332 DBL
domain from adult plasma displaying reactivity towards the
region in ELISA-assays. These antibodies were subsequently
probed on a peptide array of 52 overlapping 15-mers
(spanning amino acids 1–219 of Pf332). The Pf332-DBL
antibodies recognized two overlapping peptides, having the
sequence KKDEYIDIQSRV in common (Figure 4(a)). When
mapped on the 3D model of Pf332-DBL, the epitope was
found to be located on one of the two antiparallel α-helices
in subdomain 3 (Figure 4(b)). To rule out the possibility of
cross-reactivitywithepitopesintheDBLdomainsoftheEBL
family of invasion proteins, we also probed a peptide array
of 15-mers spanning amino acids 145–747 covering both the
F1 and F2-domain of EBA-175, with the human antibodies.
The anti-Pf332 antibodies did not bind to any of the EBA-
175 peptides, indicating that they do not cross-react with
linear epitopes of the EBL-DBLs (see Supplementary Figure1
available online at doi: 10.4061/2011/671439).
3.5. Speciﬁcity Studies of Native Pf332 Protein Expression.
In order to analyze the ability of the naturally acquired
antibodies to detect native Pf332 protein, we performed
immunoﬂuorescenceassayswiththeaﬃnity-puriﬁedhuman
anti-Pf332-DBL antibodies on air-dried monolayers of RBC
infected with the FCR3S1.2 parasite strain. At 28–32h p.i.,
the human anti-Pf332-DBL antibody reacted with Maurer’s
cleft like structures in the iRBC cytosol (Figure 5(a)).
The antibody colocalized with an antibody speciﬁc for
the Pf332 repeat region EB200, conﬁrming the speciﬁcity
of the aﬃnity-puriﬁed human anti-Pf332-DBL antibody
(Figure 5(a)).
To further investigate antibody speciﬁcity, we carried
out immunoﬂuorescence assays using a monoclonal anti-
body against Pf332-DBL and antibodies targeting the Pf332
repeats, Maurer’s clefts, and the EBL family of invasion pro-
teins. At 30–34h p.i., the anti-Pf332-DBL antibody showed
colocalization with anti-Pf332-EB200, conﬁrming that the8 Malaria Research and Treatment
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Figure 3: IgG reactivity to Pf332-DBL and PfEMP1-DBL1α in children and asymptomatic adults. Antibodies speciﬁc for Pf332-DBL and
PfEMP1-DBL1α in plasma samples collected from asymptomatic adults in Uganda, Burkina Faso, and Mali as well as from children with
mild or severe malaria in Uganda. Plasma samples were analyzed in ELISA at a dilution of 1:500. IgG reactivity is expressed as OD ratio and
calculated as follows: (OD sample − OD background)/(OD Swedish nonimmune donor pool − OD background). (a) Adults in Kampala,
Uganda; (b)children with mildor severe malaria in Apac, Uganda; (c) adults in Burkina Fasoand (d)adults in Mali.Box plots showmedians
with 25th and 75th percentiles and whiskers for 10th and 90th percentiles. ∗∗ and ∗∗∗indicate signiﬁcant diﬀerences between groups (P
< 0.01 and P < 0.001, resp.).Malaria Research and Treatment 9
Table 1: Prevalence of seropositivity for antibodies against Pf332-DBL and PfEMP1-DBL1α.
Pf332-DBL PfEMP1-DBL1α
Countries (ethnic group) n No. (%) of responders1 No. (%) of responders1 P value2
Uganda, Kampala 120 72 (60.0) 82 (68.3) ns
Uganda, Apac, mild malaria 39 29 (74.4) 28 (71.8) ns
Uganda, Apac, severe malaria 31 26 (83.9) 27 (87.1) ns
Burkina Faso (Fulani) 60 57 (95.0) 31 (51.7) <0.0001
Burkina Faso (Mossi) 48 47 (97.9) 35 (72.9) 0.0008
Mali (Fulani) 28 26 (92.9) 20 (71.4) ns
Mali (Dogon) 32 30 (93.8) 16 (50.0) 0.0002
1Cutoﬀ threshold for seropositivity was determined as the mean OD405 value plus 3 SD of a pool of nonimmune Swedish donors.
2P values by Chi-square test at a <0.05 signiﬁcance level (ns = not signiﬁcant).
monoclonal anti-DBL antibody was able to detect native
Pf332 (Figure 5(b), upper panel). Anti-Pf332-DBL further
colocalized with MAHRP1, a known Maurer’s clefts marker
in P. falciparum [37], which is in accordance with what
has previously been described for Pf332 [6, 7]( Figure 5(b),
middle panel). At 40h p.i., we could detect Pf332 in Maurer’s
cleft like structures in close proximity to the RBC plasma
membrane. These antibodies did not co-localize with anti-
EBA-175 antibodies, which gave a punctuate ﬂuorescence
pattern typical for antigens localized within the merozoite
apical complex (Figure 5(b), bottom panel), demonstrating
the lack of cross-reactivity between the two antigens.
To conﬁrm the speciﬁcity of the anti-Pf332-DBL anti-
bodies, Pf332 expression was analyzed by Western blot.
Pf332 could be detected as a high-molecular-weight band
migrating well above the 170kDa marker in FCR3S1.2
parasite extract, when probing with aﬃnity-puriﬁed human
anti-Pf332-DBL, anti-EB200, and monoclonal anti-Pf332-
DBLantibodies(Figure 5(c)).Somesmallerbands,whichare
likely processed protein or proteolytic degradation products
of full-length Pf332, were also observed. No reactivity was
detected with any of the antibodies in uninfected RBC.
4. Discussion
Although Pf332 was identiﬁed two decades ago [8–10], the
function of this giant protein still remains elusive. A number
ofpossiblefunctionshave,however,beendescribedforPf332
and among them are involvement in rigidity modiﬁcations
of iRBC [38, 39], indirect adhesion to uninfected RBC by
assisting in transportation of PfEMP1 to the iRBC surface
[38], DBL-mediated adhesion to uninfected RBC [4], and
involvement in parasite growth [4, 40–43]. Pf332 is present
inallisolatesinvestigated[4,10]indicatingthatthemolecule
is of importance for the parasite. However, Pf332 does not
seem to be essential as parasites with a disrupted Pf332 gene
arecapableofreplicatingnormallyinvitroalthoughtheiRBC
appears to be more rigid [38, 39].
To date, two diﬀerent EBL-DBL crystal structures are
known; the tandem DBL domains of P. falciparum EBA-
175 (referred to as F1 and F2) and the single DBL domain
of P. knowlesi Duﬀy-binding protein (Pkα-DBL). Despite
low sequence identity, all three DBL domains have highly
similar structures. All three share several invariant cysteine
residues, which are involved in conserved disulphide bridges,
demonstrating the importance of the cysteines in maintain-
ing the DBL fold. It is interesting that Pf332-DBL, having
only approximately 24–29% sequence identity with the DBL
domains of Pkα-DBL and EBA-175 but having the majority
of its cysteine residues at conserved locations, shares this
basic DBL-fold according to our model (Figure 2). However,
t h e r ea r es o m ed i ﬀerences between the Pf332 model and
the crystallized DBL domains. First, Pf332-DBL lacks two
cysteine residues in subdomain 1, which form a conserved
disulphide bridge in all DBL domains crystallized to date.
This disulphide bridge holds two loops together in Pkα-
DBL and EBA-175 and the lack of a disulphide bridge in
our model is likely to allow more ﬂexibility in this region
of Pf332-DBL, which could be of functional importance.
Second, Pf332-DBL has two unique cysteines in subdomain
2, which are not involved in forming a disulphide bridge in
our model, but have been predicted to do so by others [39].
The addition of a unique disulphide bridge further allows for
speculations about structural diﬀerences in the DBL domain
ofPf332comparedtotheDBLdomainsoftheEBLmembers.
Third, Pf332-DBL is missing two cysteines in subdomain 3,
which form a disulphide bridge in all three DBL domain
crystalstructuresanalyzedhere.Itseemsclearthattheoverall
structure of Pf332-DBL is similar to the DBL domains of
the EBL family. However, the structural diﬀerences observed
imply that Pf332-DBL could have a diﬀerent dynamical
behavior, leading to diﬀerences in its receptor speciﬁcity or
binding preferences.
ItisintriguingwhyPf332hasaDBLdomainhomologous
to the EBL family, although it lacks the classic EBL gene
structure and the typical EBL expression proﬁle. In contrast
to the EBL members, Pf332 contains predominantly degen-
erate repeats, which in previous studies has been shown to
bind actin and as a result, modulate the rigidity of the iRBC
[38, 39, 44]. However, a clear function for the DBL domain
hasnotbeendescribed.TheF1-domainofEBA-175isrelated
to the single DBL domain of P. vivax and P. knowlesi [3, 18],
and the domain is common to all EBLs [45]. In contrast,
the F2-domain of EBA-175 has so far only been found in P.
falciparum and P. reichenowi and the domain is suggested to
be the progenitor of var DBL [45]. It is therefore interesting10 Malaria Research and Treatment
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Figure 4:Fineepitopemappingofnaturallyacquiredhumananti-Pf332-DBLantibodiesonapeptidearray.(a)Theﬁnespeciﬁcityofhuman
aﬃnity-puriﬁed anti-Pf332-DBL antibodies was analyzed by a peptide microarray with 52 overlapping peptides of 15 amino acids shifted
by four residues covering 3D7 Pf332-DBL (amino acids 1–219). Two overlapping 15 mers having the peptide sequence KKDEYIDIQSRV in
common were recognized by the human antibodies. Nonimmune IgG gave a reactivity lower than 250 ± 200, and is therefore not displayed
in the graph. Peptides are ordered from N-terminus (top) to C-terminus (bottom). Bars represent the mean reactivity of three subarrays;
error bars indicate standard deviation. (b) Mapping of epitopes recognized by the aﬃnity-puriﬁed human anti-Pf332-DBL antibody on
the 3D model of Pf332-DBL. Subdomain 1 (yellow), subdomain 2 (red), and subdomain 3 (green). The epitope recognized by the human
aﬃnity-puriﬁed anti-Pf332-DBL antibodies (blue) is located on one of the two major α-helices in subdomain 3. Disulphide bridges are
displayed as spheres.
to note that the DBL domain of Pf332 has more similarities
to F2 than to F1 of EBA-175, as the DBL domain of antigen
332 so far only has been identiﬁed in P. falciparum, although
antigen 332 orthologues are present in species such as P.
berghei and P. yoelii [46].
OurdatashowthatantibodiestoPf332-DBLarefrequent
in plasma from individuals residing in distinct malaria
endemic regions, demonstrating that it is immunogenic.
The frequent seropositivity is also in accordance with the
domain being conserved and having very few polymor-
phisms observed [4]. The lack of variation in the DBL
domain of Pf332 suggests that the protein is concealed
from the immune system and therefore is not under any
selective pressure. As a result, it is likely that antibodies
towards the antigen are generated upon schizont rupture,
at which time the protein is released into the extracellular
environment. Previous studies using recombinant protein of
the Pf332 regions EB200 and C231 (a C-terminally located
region of Pf332, less rich in degenerate-repeats [47]), have
reported that children lack antibodies against both parts of
the molecule. However, antibodies were frequently found
in older individuals, indicating a slow acquisition of Pf332
antibodies [14, 48]. Our results show that children living
in Apac, a highly endemic region in Uganda experiencing
the highest entomological inoculation rate reported in
Africa [29], had developed antibodies to both Pf332-DBL
and PfEMP1-DBL already at a very young age. Due to
conservation of Pf332-DBL, antibodies should be acquired
early in life in nonimmune children and particularly in areas
of high malaria endemicity, which is conﬁrmed by our study.
It must, however, be taken into consideration that plasma
samples were collected from children with an ongoing P.
falciparum infection where the host immune system had
been recently boosted. High levels of antibodies against
PfEMP1-DBL1α were also frequently found among children
in the Apac area, although the sequence diversity of this
domain is great. This might be a result of cross-reactivity to
similar PfEMP1 variants.Malaria Research and Treatment 11
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Figure 5: Detection of native Pf332 in immunoﬂuorescence assays and Western blot. Protein expression of Pf332 in FCR3S1.2 infected
red blood cells (iRBC). (a) Immunoﬂuorescence analysis on air-dried monolayers of iRBC (28–32h p.i.) with human aﬃnity-puriﬁed anti-
Pf332-DBL antibodies (red) and anti-Pf332-EB200 (green). The parasite was counterstained with DAPI (blue). The antibodies colocalized
well and detected Pf332 in Maurer’s cleft like structures in the iRBC cytosol. (b) At 30–34h p.i., a monoclonal antibody against Pf332-DBL
(red) showed colocalization with both anti-Pf332-EB200 (green; upper panel) and anti-MAHRP1, a known Maurer’s cleft marker (green;
middle panel). In schizonts, anti-Pf332-DBL (red) could be detected in Maurer’s clefts in close proximity to the RBC plasma membrane.
These antibodies did not co-localize with anti-EBA-175 antibodies (green), which gave a punctuate ﬂuorescence pattern typical for antigens
localized within the merozoite apical complex. The parasite was counterstained with DAPI (blue). Scale bar indicates 5μm. (c) Western blot
analysis of Pf332 expression in FCR3S1.2 iRBC (36–40h p.i.). Membranes were probed with human aﬃnity-puriﬁed anti-Pf332-DBL (lane
1 and 2), polyclonal anti-Pf332-EB200 (lane 3 and 4), and monoclonal anti-Pf332-DBL (lane 5 and 6). Bands corresponding to full length
Pf332 are indicated. All three antibodies recognized Pf332 migrating well above the 170kDa marker. None of the antibodies reacted with
uninfected RBC.
Antibodies against the DBL domain of Pf332 were highly
prevalent among individuals in both Burkina Faso and Mali
regardless of their ethnic group and antibodies occurred
at very high titers. In contrast, the responder frequency to
PfEMP1-DBL1α diﬀered considerably between the ethnic
groups. One explanation might be that although living close
to each other geographically and experiencing the same
malaria transmission rate, the diﬀerent tribes had encoun-
teredparasitespresentingdiﬀerentPfEMP1moleculesonthe
iRBC surface. Whilst the Pf332 gene is present as a single
copy gene in most parasite isolates studied so far [9], the
var genes encoding the PfEMP1 molecule are present in
approximately 60 copies per genome [49, 50]. In Mali, the
Fulani who are less susceptible to malaria were found to have
signiﬁcantly higher antibody levels to PfEMP1-DBL1α than
their sympatric tribe Dogon. Further, the Fulani were more
seropositive, indicating either that they more frequently had
encountered parasites expressing this particular or similar
subtypes of PfEMP1 to which they had acquired antibodies,
or that they more easily develop high levels of antibodies,
which could be an explanation for their lower susceptibility
to malaria.
Studies on Pf332 have been hampered by the cross-
reactive nature of the antigen due to its high content of
negatively charged repeats, which are present in several
malaria antigens. The DBL domain of Pf332 is conserved
between diﬀerent parasite isolates, thus enabling more anti-
genspeciﬁcstudies.Inaneﬀorttolookatantibodyspeciﬁcity
and to exclude the possibility of cross-reactivity to DBL
domains of the EBL family of invasion proteins, we aﬃnity-
puriﬁed human antibodies using the DBL domain of Pf332
and analyzed them in peptide arrays, immunoﬂuorescence
microscopy assays, and Western blotting. From the peptide
microarray it was evident that the antibodies only reacted12 Malaria Research and Treatment
with epitopes found in Pf332 and not in DBL domains of
the EBL family of invasion proteins, here represented by the
tandem DBL domains of EBA-175 (Figure 4 and Supple-
mentary Figure1). This method only takes linear epitopes
into consideration; however, it gives a strong indication
that there is very little or no cross-reactivity between the
DBL domains of Pf332 and the EBL family. The lack of
cross-reactivity when using native protein was conﬁrmed
by immunoﬂuorescence microscopy and Western blotting
(Figure 5), which concludes that antibodies raised against
the DBL domain of Pf332 do not cross-react with the DBL
domains of the EBL family.
5. Conclusions
In summary, the DBL domain represents a conserved region
of the Pf332 molecule, with a similar structure to the DBL
domains of EBA-175 and Pkα-DBP according to our 3D
predictions. Antibodies towards the domain are acquired
early in life in areas of high endemicity and antibodies
are commonly found in semi-immune adults. Moreover,
antibodies towards Pf332-DBL are antigen speciﬁc and
do not display cross-reactivity with DBL-containing EBL
proteins. Hence, the DBL domain of Pf332 is expected to
greatly facilitate further investigations of Pf332; including its
function and potential role in immunity to malaria.
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